Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 6 | 0 | 5 | 0 | 1 |
Analyst Firms Making Recommendations1
- RBC Capital
- JP Morgan
- Goldman Sachs
- BMO Capital
- Morgan Stanley
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Chemours
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 12/01/2023 | CC | Buy Now | Chemours | $28.90 | 38.41% | RBC Capital | Arun Viswanathan | $28 → $40 | Upgrade | Sector Perform → Outperform | Get Alert |
| 11/07/2023 | CC | Buy Now | Chemours | $28.90 | -10.03% | JP Morgan | Jeffrey Zekauskas | $38 → $26 | Maintains | Neutral | Get Alert |
| 10/31/2023 | CC | Buy Now | Chemours | $28.90 | 3.81% | Goldman Sachs | Duffy Fischer | $35 → $30 | Maintains | Neutral | Get Alert |
| 10/30/2023 | CC | Buy Now | Chemours | $28.90 | -3.11% | RBC Capital | Arun Viswanathan | $30 → $28 | Maintains | Sector Perform | Get Alert |
| 10/30/2023 | CC | Buy Now | Chemours | $28.90 | 34.95% | BMO Capital | John McNulty | $45 → $39 | Maintains | Outperform | Get Alert |
| 10/30/2023 | CC | Buy Now | Chemours | $28.90 | -3.11% | Morgan Stanley | Vincent Andrews | $33 → $28 | Maintains | Equal-Weight | Get Alert |
| 10/30/2023 | CC | Buy Now | Chemours | $28.90 | -3.11% | Barclays | Michael Leithead | $31 → $28 | Maintains | Equal-Weight | Get Alert |
| 10/04/2023 | CC | Buy Now | Chemours | $28.90 | 7.27% | Barclays | Michael Leithead | $40 → $31 | Maintains | Equal-Weight | Get Alert |
| 08/02/2023 | CC | Buy Now | Chemours | $28.90 | 83.39% | BMO Capital | John McNulty | $64 → $53 | Maintains | Outperform | Get Alert |
| 08/01/2023 | CC | Buy Now | Chemours | $28.90 | 14.19% | Morgan Stanley | Vincent Andrews | $33 → $33 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/31/2023 | CC | Buy Now | Chemours | $28.90 | 38.41% | RBC Capital | Arun Viswanathan | $37 → $40 | Maintains | Sector Perform | Get Alert |
| 07/19/2023 | CC | Buy Now | Chemours | $28.90 | 14.19% | Morgan Stanley | Vincent Andrews | $33 → $33 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 07/11/2023 | CC | Buy Now | Chemours | $28.90 | 38.41% | Barclays | Michael Leithead | $38 → $40 | Maintains | Equal-Weight | Get Alert |
| 06/22/2023 | CC | Buy Now | Chemours | $28.90 | 28.03% | B of A Securities | Matthew DeYoe | $41 → $37 | Downgrade | Buy → Neutral | Get Alert |
| 06/13/2023 | CC | Buy Now | Chemours | $28.90 | 48.79% | UBS | Joshua Spector | $41 → $43 | Maintains | Buy | Get Alert |
| 06/09/2023 | CC | Buy Now | Chemours | $28.90 | 28.03% | RBC Capital | Arun Viswanathan | $36 → $37 | Maintains | Sector Perform | Get Alert |
| 06/05/2023 | CC | Buy Now | Chemours | $28.90 | 121.45% | BMO Capital | John McNulty | $54 → $64 | Maintains | Outperform | Get Alert |
| 05/31/2023 | CC | Buy Now | Chemours | $28.90 | 3.81% | JP Morgan | Jeffrey Zekauskas | $35 → $30 | Maintains | Neutral | Get Alert |
| 05/01/2023 | CC | Buy Now | Chemours | $28.90 | 24.57% | RBC Capital | Arun Viswanathan | $35 → $36 | Maintains | Sector Perform | Get Alert |
What is the target price for Chemours (CC)?
The latest price target for Chemours (NYSE: CC) was reported by RBC Capital on December 1, 2023. The analyst firm set a price target for $40.00 expecting CC to rise to within 12 months (a possible 38.41% upside). 30 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Chemours (CC)?
The latest analyst rating for Chemours (NYSE: CC) was provided by RBC Capital, and Chemours upgraded their outperform rating.
When is the next analyst rating going to be posted or updated for Chemours (CC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Chemours, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Chemours was filed on December 1, 2023 so you should expect the next rating to be made available sometime around December 1, 2024.
Is the Analyst Rating Chemours (CC) correct?
While ratings are subjective and will change, the latest Chemours (CC) rating was a upgraded with a price target of $28.00 to $40.00. The current price Chemours (CC) is trading at is $28.90, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.